医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Meiji Seika Pharma to Launch Two Products from Santen Pharmaceutical Co., Ltd. in Indonesia

2019年08月07日 AM10:00
このエントリーをはてなブックマークに追加


 

JAKARTA, Indonesia

Meiji Seika Pharma Co., Ltd. “Meiji” has announced that it launched the following two products from Santen Pharmaceutical Co., Ltd. “Santen” in Indonesia, based on a working business agreement that Meiji entered in November of 2018 with Santen.

Dry-eye treatment
DIQUAS ophthalmic solution 3%
(Diquafosol Sodium)

Glaucoma and ocular hypertension treatment
TAFLOTAN ophthalmic solution 0.0015%
(Tafluprost)

Based on the working business agreement with Santen, these products will be marketed in Indonesia by Meiji’s affiliated subsidiary, PT. Meiji Indonesian Pharmaceutical Industries “PT. Meiji”. PT. Meiji established a new marketing team specialized on ophthalmic treatments, and Santen will support their marketing activities. Moving forward, PT. Meiji will continue to add more products and expand the product lineup. PT. Meiji and Santen work together to expand market share in Indonesia for ophthalmic products.

Meiji and Santen, through the marketing of ophthalmic treatments in Indonesia, are contributing to the health of the peoples of ASEAN countries.

About Meiji Seika Pharma Co., Ltd
Address: Chuo-ku, Tokyo Japan
President and CEO: Daikichiro Kobayashi
https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

About Santen Pharmaceutical Co., Ltd.

Address: Kita-ku, Osaka Japan
President and CEO: Akira Kurokawa
https://www.santen.com/en/

About PT. Meiji Indonesian Pharmaceutical Industries
Established: 1974
Address: Jalan Prof. Dr. Soepomo No. 40, Tebet, Jakarta Selatan, 12870 Indonesia
President Director: Masanobu Sato
Employees: 799, as of March, 2019
Parent Company: Meiji Seika Pharma Co., Ltd.

Scope of Business: Manufacture, sales, and export of medical products and materials
https://meiji.co.id/id

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190806005344/en/

CONTACT

Meiji Seika Pharma Co., Ltd.

Masashi Ohnishi

Public Relations

pr-pharma@meiji.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高